Targeted literature review of the humanistic and economic burden of adult growth hormone deficiency.

BACKGROUND: Quality of life (QoL) and health economic data are becoming increasingly important factors in healthcare decision-making. While there is a wealth of information establishing the benefit of growth hormone (GH) replacement therapy on adults with growth hormone deficiency (aGHD), recent reviews on the QoL and health economic impact of aGHD and the effect of treatment on these factors is limited.

OBJECTIVE: The aim of this article is to summarise the impact of early and sustained treatment on the QoL and economic burden of aGHD by conducting a targeted literature review.

METHODS: Standard electronic databases, including PubMed and the Cochrane collaboration website, were searched for publications between January 2006 and July 2016 for evidence of the humanistic and economic burden of aGHD. Search terms included growth hormone deficiency, health-related quality of life, HRQoL, patient-reported outcomes, outcome assessment, well-being and adherence.

RESULTS: The literature search identified 732 initial hits and a final 14 publications were included. The analysis showed that the economic burden of aGHD is largely driven by the productivity losses associated with the disease. This is because most patients with aGHD are of working age and the QoL domains (memory & concentration and energy & vitality) most commonly affected by aGHD severely impair a person's ability to work and may limit their contribution to society.

CONCLUSION: Untreated aGHD can seriously affect patient's functioning. Early and continued treatment with GH replacement therapy could potentially improve the QoL and reduce the economic burden associated with the aGHD. This review has limitations; only English language articles published since January 2006 were included although many of the studies were conducted in the Nordic countries; it is unclear how representative these studies are of the population as a whole. This was a literature review and not a systematic review, as it was thought to be unlikely that in this rare disease, any additional publications would have been identified. Overall, this review reveals a paucity of data in this underserved population and points to research gaps which could be addressed with new studies.